Kronox Lab Sciences Limited Open Offer Seeks 25.79% at ₹157.27

Kronox Lab Sciences Limited is subject to a ₹150.5 crore open offer for up to 25.79% of its voting share capital at ₹157.27 per share, following an agreement under which Indo Borax and Chemicals Limited will acquire a 64.26% promoter stake for ₹246.1 crore.

What does the Kronox Lab Sciences Limited open offer involve?

Kronox Lab Sciences Limited's open offer allows Indo Borax and Chemicals Limited, along with Zenrock Chemicals Private Limited as a person acting in concert, to acquire up to 95.70 lakh fully paid-up equity shares from public shareholders. The offer is being managed by IIFL Capital Services Limited and is being made under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The offer price is ₹157.27 per equity share, payable in cash. Assuming full acceptance, the offer consideration is ₹150.5 crore. The shares sought represent 25.79% of Kronox Lab Sciences Limited's voting share capital. The company is listed and its trading status remains active.

IIFL Capital Services Limited submitted the Letter of Offer to BSE on October 29, 2026. The disclosed schedule indicates that shareholders can tender shares until November 20, 2026, with settlement due within 10 working days after the offer closes, subject to applicable regulations and escrow arrangements.

Why was the open offer triggered?

The open offer was triggered by a share purchase agreement dated August 20, 2026, under which Indo Borax and Chemicals Limited and Zenrock Chemicals Private Limited agreed to acquire a controlling promoter stake in Kronox Lab Sciences Limited. The agreement covers 2.38 crore shares, representing 64.26% of the company, from three existing promoters.

The promoter-share transaction has a stated value of ₹246.1 crore and was agreed at ₹103.22 per share. The acquisition of this stake led to the mandatory open-offer process for public shareholders under the takeover regulations cited in the disclosures.

Indo Borax's board approved the open offer, with Zenrock acting in concert with the acquirer. The public announcement was issued in August, followed by the detailed public statement and a draft Letter of Offer in September. The October 29 filing of the Letter of Offer represents the next disclosed procedural stage.

How does the offer schedule compare with earlier disclosures?

The current disclosed timetable places the tendering deadline on November 20, 2026, while the earlier draft Letter of Offer carried a tentative tendering period from October 15 to October 29, 2026. The later Letter of Offer submission and related update provide the relevant timeline stated in the supplied announcement.

The identified date in the earlier tentative schedule was September 30, 2026. The documents also state that acceptance is assured for valid tenders up to the maximum number of shares covered by the offer. Any tendering, acceptance and settlement will remain subject to the conditions and process specified in the offer documents and SEBI regulations.

The disclosed offer size is 25.79% of voting capital. The source material notes that this is below the 26% minimum referenced under the SEBI takeover framework. The available announcement does not provide further explanation of this difference, and shareholders would need to rely on the Letter of Offer and regulatory disclosures for the applicable terms.

What does the transaction mean for shareholders and investors?

For eligible public shareholders, the offer provides a cash tendering route at ₹157.27 a share for up to 95.70 lakh shares. The offer price is higher than the ₹103.22 per-share price disclosed for the promoter stake purchase, although the transactions concern different blocks of shares and terms.

The principal ownership change is the proposed 64.26% acquisition from the existing promoters. If completed under the agreement's stated conditions, that transaction would establish Indo Borax as the controlling acquirer, with Zenrock participating as the named person acting in concert.

For investors, the filings clarify the volume sought, the cash consideration and the scheduled closure date. They do not provide a forecast of Kronox Lab Sciences Limited's future earnings, operational strategy, management structure or subsequent shareholding beyond the announced acquisition and open-offer arrangements.

What is the regulatory and company background?

Kronox Lab Sciences Limited is a Gujarat-based listed company with its registered office at Ekalbara, Padra, Vadodara. Its equity shares have a face value of ₹10 each. The company had also disclosed receipt of the draft Letter of Offer from IIFL Capital Services Limited on September 4, 2026.

The open offer follows the sequence set out in the SEBI takeover regulations: a public announcement, a detailed public statement, a draft Letter of Offer and the Letter of Offer to public shareholders. These disclosures set out the acquirer, person acting in concert, price, maximum offer size and tendering process.

The latest cited company update before the Letter of Offer was a corporate announcement on operational performance and quarterly growth published on October 9, 2026. That update is separate from the takeover process. The supplied material does not link the operational announcement to the proposed promoter-stake sale or open offer.

Conclusion

The Kronox Lab Sciences Limited transaction combines a proposed ₹246.1 crore acquisition of a 64.26% promoter stake with a public open offer for up to 95.70 lakh shares at ₹157.27 each. The offer has a maximum consideration of ₹150.5 crore and gives public shareholders a defined tendering mechanism within the announced process.

The immediate date to watch is November 20, 2026, the disclosed deadline for tendering shares. Shareholders should also monitor BSE filings for details on valid acceptances, settlement within the indicated 10-working-day period, statutory conditions and updates on completion of the promoter-share acquisition.